Healthcare Triangle, Inc. to Participate at the 2024 MUSE Executive Institute
PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader...
News
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients...
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Smart for Life Announces Completion of Audit for Pending Acquisition
Acquisition Expected to Contribute More than $8 Million of Annualized Revenue and Positive Net IncomeMIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE)...
Stryker to announce financial results for its fourth quarter and full year 2023
Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter...
First ReWalk Personal Exoskeleton Claim Paid by Medicare
ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injuryMARLBOROUGH, Mass. and...
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests...
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel...
CervoMed to Participate in the Emerging Growth Conference 66
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Compass Therapeutics Provides Corporate Update
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on...
Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue
Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix GoSAN FRANCISCO, Jan. 05, 2024 (GLOBE...
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
RJVA-001 is the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate to be nominated by the Company and is designed...